<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431999</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02706-51</org_study_id>
    <nct_id>NCT04431999</nct_id>
  </id_info>
  <brief_title>Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage</brief_title>
  <acronym>T-STORHM</acronym>
  <official_title>Evaluation of a Transfusion Therapy Using Whole Blood Versus Fractionated Blood Products in the Management of Coagulopathy in Patients Admitted to Hospital for Acute Traumatic Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TIMC-IMAG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Floralis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of traumatized hemorrhages is correlated with the nature of transfusion
      therapy: a 50% reduction in mortality for an early and massive supply of plasma, and 20% for
      an early and massive supply of platelets. However, this strategy encounters logistical
      difficulties, particularly in a context of collective emergency (attacks). The use of whole
      blood, widely documented by the Armed Forces, improves the availability of plasma and
      platelets, and simplifies handling by the various actors in the chain.

      T-STORHM is a randomized, controlled, parallel clinical trial.This study tests
      non-inferiority of whole blood transfusion therapy in the management of coagulopathy in
      patients with acute traumatic hemorrhage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, terrorist attacks have confronted the investigator's healthcare system with
      a massive influx of victims of war weapon injuries. This new fact makes the efficiency of
      transfusion therapy crucial: hemorrhage is the leading cause of death from weapons of war,
      and the high number of victims of each attack changes the logistical approach.

      The logistical problems with transfusion therapy, including red blood cell (PRBCs), plasma
      and platelet concentrates, are the speed of delivery and availability. Using whole blood is a
      pragmatic solution to overcome these problems. This solution has been used for many years by
      the French Army to ensure platelet transfusion in traumatic hemorrhages

      The hypothesis of the T-STORHM study is that the use of whole blood is a solution in a
      context of civil trauma not effective less than component therapy (PRBCs, plasma and platelet
      concentrates) in the management of coagulopathy in patients admitted to hospital for
      traumatic hemorrhage.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, Controlled, Randomized, Open Labe Therapeutic Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non inferiority on the correction of coagulopathy, during emergency transfusion of bleeding trauma using whole blood compared to the use of component therapy (packed red blood cells, plasma units and platelets).</measure>
    <time_frame>6 hours following hospital admission</time_frame>
    <description>This outcome is measured on the correction of traumatic coagulopathy, measured by the value of a viscoelastometric parameter : the maximum amplitude (MA) (measured by a thromboelastogram).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of circulatory resuscitation</measure>
    <time_frame>2 hours following hospital admission</time_frame>
    <description>Proportion of patients with lactate clearance &gt; 20% per hour at H2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 hours following hospital admission and Day 30 (or the last day of hospitalization)</time_frame>
    <description>Number of deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality / Morbidity</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>Composite endpoint : Number of deaths at H24 or impairment of vital functions with a Sequential Organ Failure Assessment (SOFA) score greater than or equal to 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on timeframe to obtain blood products</measure>
    <time_frame>2 and 6 hours following hospital admission</time_frame>
    <description>Time to obtain product ratios in accordance with recommendations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on time to start transfusion therapy</measure>
    <time_frame>Time between admission and transfusion therapy</time_frame>
    <description>Time to start transfusion therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of coagulopathy.</measure>
    <time_frame>At inclusion, 2, 6 and 24 hours following hospital admission</time_frame>
    <description>All the parameters of the thrombelastography (TEG) (R/CK, alpha/CK, MA/CRT, LY30/CK, FF/CRT) allow to evaluate the coagulopathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of coagulopathy</measure>
    <time_frame>At inclusion, 2, 6 and 24 hours following hospital admission.</time_frame>
    <description>All the parameters of the coagulation (PT, APTT, fibrinogene) allow to evaluate the coagulopathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of whole blood transfusion</measure>
    <time_frame>Day 1, Day 2</time_frame>
    <description>Hemolysis marker rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Labile blood products transfused in the first 24 hours</measure>
    <time_frame>24 hours following hospital admission</time_frame>
    <description>Number of bags administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the strategy</measure>
    <time_frame>Day 30 (or the last day of hospitalization)</time_frame>
    <description>Direct costs of transfusion and the cost of the ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biobank establishment</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>To constitute biobank for biological measurements in research hemorrhagic shock pathophysiology of transfusion resuscitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ancillary study n°1 : recirculation of storage microerythrocytes</measure>
    <time_frame>before and after transfusion resuscitation, Day 30 (or the last day of hospitalization).</time_frame>
    <description>Rate of storage microerythrocytes, monocyte quantification and phenotyping, splenic ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ancillary study n°2 : evolution of microcirculation during transfusion resuscitation of hemorrhagic shock.</measure>
    <time_frame>During the transfusion resuscitation</time_frame>
    <description>Optical imaging technique of microvascular content to detect flow anomalies in microvessels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Trauma</condition>
  <condition>Acute Hemorrhage</condition>
  <condition>Coagulopathy</condition>
  <arm_group>
    <arm_group_label>Whole blood group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Damage control resuscitation for trauma care using whole blood.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fractionated blood products group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Damage control resuscitation for trauma care using component therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Whole blood transfusion</intervention_name>
    <description>Severe trauma patients with a life threatening bleeding will be managed with 3 whole blood bags for the 1st and 2nd pack. The later packs will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.</description>
    <arm_group_label>Whole blood group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fractionated blood products transfusion</intervention_name>
    <description>Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.</description>
    <arm_group_label>Fractionated blood products group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Severe trauma patients requiring the initiation of a massive transfusion protocol
        determined on

          1. At least two Red flag score factors (according to pre-hospital data) :

               -  Suspected pelvic fracture

               -  Shock index (FC / PAS)&gt; = 1

               -  Microdose hemoglobin &lt;13g

               -  Average blood pressure &lt;70 mmHg

               -  Need for prehospital tracheal intubation

          2. AND at least two criteria of the Assessment of Blood Consumption (ABC) score
             established at the patient's arrival:

               -  Penetrating trauma

               -  Focused Abdominal Sonography for Trauma (FAST) echo positive

               -  Blood pressure &lt;90 mmHg

               -  Respiratory rate &gt;120 bpm

          3. AND/OR on the prediction of the practitioner (clinical diagnosis) in charge of the
             treatment of the injured person of the need to transfuse at least 4 PRBCs within 6
             hours after the admission of the trauma patient

        Exclusion Criteria:

          -  Non-traumatic hemorrhage

          -  Patients transfused with more than two PRBCs before the initiation of the massive
             transfusion protocol.

          -  Anti-coagulation treatment

          -  Pregnancy

          -  Age &lt; 18 years

          -  Patient refusing administration of blood products

          -  Patient transferred from another hospital

          -  Patient nor transported by a physician-staffed prehospital emergency medical system

          -  Burn patient (≥30% of body surface).

          -  No affiliated to the social security

          -  Person deprived of liberty by a legal or administrative decision, person under
             guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé FOEHRENBACH</last_name>
    <role>Study Director</role>
    <affiliation>Direction Centrale du Service de Santé des Armées (DCSSA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvain AUSSET</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ecoles militaires de santé de Lyon-Bron</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Luc BOSSON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Statistical and methodological investigator - Laboratoire TIMC UMR 5525 CNRS Equipe Themas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain AUSSET</last_name>
    <phone>+33 4 72 36 40 01</phone>
    <email>sylvain.ausset@def.gouv.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe RENARD</last_name>
    <phone>+33 1 40 51 41 03</phone>
    <email>christophe1.renard@intradef.gouv.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de La Cavale Blanche - Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier HUET</last_name>
      <email>olivier.huet@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre PASQUIER</last_name>
      <email>pierre.pasquier@intradef.gouv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre BOUZAT</last_name>
      <email>PBouzat@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU du Kremlin Bicêtre</name>
      <address>
        <city>Paris</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu RAUX</last_name>
      <email>mathieu.raux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Sainte Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric Meaudre</last_name>
      <email>eric.meaudre-desgouttes@intradef.gouv.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Spinella PC. Zero preventable deaths after traumatic injury: An achievable goal. J Trauma Acute Care Surg. 2017 Jun;82(6S Suppl 1):S2-S8. doi: 10.1097/TA.0000000000001425.</citation>
    <PMID>28333835</PMID>
  </reference>
  <reference>
    <citation>Bhangu A, Nepogodiev D, Doughty H, Bowley DM. Meta-analysis of plasma to red blood cell ratios and mortality in massive blood transfusions for trauma. Injury. 2013 Dec;44(12):1693-9. doi: 10.1016/j.injury.2012.07.193. Epub 2012 Sep 25. Review.</citation>
    <PMID>23021369</PMID>
  </reference>
  <reference>
    <citation>Johansson PI, Oliveri RS, Ostrowski SR. Hemostatic resuscitation with plasma and platelets in trauma. J Emerg Trauma Shock. 2012 Apr;5(2):120-5. doi: 10.4103/0974-2700.96479.</citation>
    <PMID>22787340</PMID>
  </reference>
  <reference>
    <citation>Cap A, Hunt B. Acute traumatic coagulopathy. Curr Opin Crit Care. 2014 Dec;20(6):638-45. doi: 10.1097/MCC.0000000000000158. Review.</citation>
    <PMID>25340382</PMID>
  </reference>
  <reference>
    <citation>Cap AP, Pidcoke HF, Spinella P, Strandenes G, Borgman MA, Schreiber M, Holcomb J, Tien HC, Beckett AN, Doughty H, Woolley T, Rappold J, Ward K, Reade M, Prat N, Ausset S, Kheirabadi B, Benov A, Griffin EP, Corley JB, Simon CD, Fahie R, Jenkins D, Eastridge BJ, Stockinger Z. Damage Control Resuscitation. Mil Med. 2018 Sep 1;183(suppl_2):36-43. doi: 10.1093/milmed/usy112.</citation>
    <PMID>30189070</PMID>
  </reference>
  <reference>
    <citation>Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, Komadina R, Maegele M, Nardi G, Riddez L, Samama CM, Vincent JL, Rossaint R. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019 Mar 27;23(1):98. doi: 10.1186/s13054-019-2347-3.</citation>
    <PMID>30917843</PMID>
  </reference>
  <reference>
    <citation>Godier A, Bacus M, Kipnis E, Tavernier B, Guidat A, Rauch A, Drumez E, Susen S, Garrigue-Huet D. Compliance with evidence-based clinical management guidelines in bleeding trauma patients. Br J Anaesth. 2016 Nov;117(5):592-600.</citation>
    <PMID>27799173</PMID>
  </reference>
  <reference>
    <citation>Stanworth SJ, Davenport R, Curry N, Seeney F, Eaglestone S, Edwards A, Martin K, Allard S, Woodford M, Lecky FE, Brohi K. Mortality from trauma haemorrhage and opportunities for improvement in transfusion practice. Br J Surg. 2016 Mar;103(4):357-65. doi: 10.1002/bjs.10052. Epub 2016 Feb 3.</citation>
    <PMID>26841720</PMID>
  </reference>
  <reference>
    <citation>Carli P, Pons F, Levraut J, Millet B, Tourtier JP, Ludes B, Lafont A, Riou B. The French emergency medical services after the Paris and Nice terrorist attacks: what have we learnt? Lancet. 2017 Dec 16;390(10113):2735-2738. doi: 10.1016/S0140-6736(17)31590-8. Epub 2017 Jul 25.</citation>
    <PMID>28754492</PMID>
  </reference>
  <reference>
    <citation>Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, Mallett O, Zubko T, Oetjen-Gerdes L, Rasmussen TE, Butler FK, Kotwal RS, Holcomb JB, Wade C, Champion H, Lawnick M, Moores L, Blackbourne LH. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012 Dec;73(6 Suppl 5):S431-7. doi: 10.1097/TA.0b013e3182755dcc. Erratum in: J Trauma Acute Care Surg. 2013 Feb;74(2):706. Kotwal, Russell S [corrected to Kotwal, Russ S].</citation>
    <PMID>23192066</PMID>
  </reference>
  <reference>
    <citation>Eastridge BJ, Hardin M, Cantrell J, Oetjen-Gerdes L, Zubko T, Mallak C, Wade CE, Simmons J, Mace J, Mabry R, Bolenbaucher R, Blackbourne LH. Died of wounds on the battlefield: causation and implications for improving combat casualty care. J Trauma. 2011 Jul;71(1 Suppl):S4-8. doi: 10.1097/TA.0b013e318221147b.</citation>
    <PMID>21795876</PMID>
  </reference>
  <reference>
    <citation>Glasgow S, Davenport R, Perkins Z, Tai N, Brohi K. A comprehensive review of blood product use in civilian mass casualty events. J Trauma Acute Care Surg. 2013 Sep;75(3):468-74. doi: 10.1097/TA.0b013e318298efb9. Review.</citation>
    <PMID>23928738</PMID>
  </reference>
  <reference>
    <citation>Doughty H, Glasgow S, Kristoffersen E. Mass casualty events: blood transfusion emergency preparedness across the continuum of care. Transfusion. 2016 Apr;56 Suppl 2:S208-16. doi: 10.1111/trf.13488. Review.</citation>
    <PMID>27100758</PMID>
  </reference>
  <reference>
    <citation>Glasgow SM, Allard S, Rackham R, Doughty H. Going for gold: blood planning for the London 2012 Olympic Games. Transfus Med. 2014 Jun;24(3):145-53. doi: 10.1111/tme.12116. Epub 2014 Apr 18. Review.</citation>
    <PMID>24750387</PMID>
  </reference>
  <reference>
    <citation>Glasgow SM, Allard S, Doughty H, Spreadborough P, Watkins E. Blood and bombs: the demand and use of blood following the London Bombings of 7 July 2005--a retrospective review. Transfus Med. 2012 Aug;22(4):244-50. doi: 10.1111/j.1365-3148.2012.01173.x. Review.</citation>
    <PMID>22809430</PMID>
  </reference>
  <reference>
    <citation>Radwan ZA, Bai Y, Matijevic N, del Junco DJ, McCarthy JJ, Wade CE, Holcomb JB, Cotton BA. An emergency department thawed plasma protocol for severely injured patients. JAMA Surg. 2013 Feb;148(2):170-5. doi: 10.1001/jamasurgery.2013.414.</citation>
    <PMID>23426594</PMID>
  </reference>
  <reference>
    <citation>de Biasi AR, Stansbury LG, Dutton RP, Stein DM, Scalea TM, Hess JR. Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma (CME). Transfusion. 2011 Sep;51(9):1925-32. doi: 10.1111/j.1537-2995.2010.03050.x. Epub 2011 Feb 18.</citation>
    <PMID>21332727</PMID>
  </reference>
  <reference>
    <citation>Cardenas JC, Zhang X, Fox EE, Cotton BA, Hess JR, Schreiber MA, Wade CE, Holcomb JB; PROPPR Study Group. Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial. Blood Adv. 2018 Jul 24;2(14):1696-1704. doi: 10.1182/bloodadvances.2018017699.</citation>
    <PMID>30030268</PMID>
  </reference>
  <reference>
    <citation>Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, Cohen MJ, Cotton BA, Fabian TC, Inaba K, Kerby JD, Muskat P, O'Keeffe T, Rizoli S, Robinson BR, Scalea TM, Schreiber MA, Stein DM, Weinberg JA, Callum JL, Hess JR, Matijevic N, Miller CN, Pittet JF, Hoyt DB, Pearson GD, Leroux B, van Belle G; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015 Feb 3;313(5):471-82. doi: 10.1001/jama.2015.12.</citation>
    <PMID>25647203</PMID>
  </reference>
  <reference>
    <citation>Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, Alarcon LH, Bai Y, Brasel KJ, Bulger EM, Cotton BA, Matijevic N, Muskat P, Myers JG, Phelan HA, White CE, Zhang J, Rahbar MH; PROMMTT Study Group. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013 Feb;148(2):127-36.</citation>
    <PMID>23560283</PMID>
  </reference>
  <reference>
    <citation>Cap AP, Spinella PC, Borgman MA, Blackbourne LH, Perkins JG. Timing and location of blood product transfusion and outcomes in massively transfused combat casualties. J Trauma Acute Care Surg. 2012 Aug;73(2 Suppl 1):S89-94. doi: 10.1097/TA.0b013e318260625a.</citation>
    <PMID>22847102</PMID>
  </reference>
  <reference>
    <citation>Fox EE, Holcomb JB, Wade CE, Bulger EM, Tilley BC; PROPPR Study Group. Earlier Endpoints are Required for Hemorrhagic Shock Trials Among Severely Injured Patients. Shock. 2017 May;47(5):567-573. doi: 10.1097/SHK.0000000000000788.</citation>
    <PMID>28207628</PMID>
  </reference>
  <reference>
    <citation>Novak DJ, Bai Y, Cooke RK, Marques MB, Fontaine MJ, Gottschall JL, Carey PM, Scanlan RM, Fiebig EW, Shulman IA, Nelson JM, Flax S, Duncan V, Daniel-Johnson JA, Callum JL, Holcomb JB, Fox EE, Baraniuk S, Tilley BC, Schreiber MA, Inaba K, Rizoli S, Podbielski JM, Cotton BA, Hess JR; PROPPR Study Group. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. Transfusion. 2015 Jun;55(6):1331-9. doi: 10.1111/trf.13098. Epub 2015 Mar 30.</citation>
    <PMID>25823522</PMID>
  </reference>
  <reference>
    <citation>Daban JL, Kerleguer A, Clavier B, Salliol A, Ausset S. [Fresh whole blood transfusion for war surgery: the experience of the Kabul French combat support hospital from 2006 to 2009]. Ann Fr Anesth Reanim. 2012 Nov;31(11):850-6. doi: 10.1016/j.annfar.2012.07.014. Epub 2012 Sep 1. French.</citation>
    <PMID>22943967</PMID>
  </reference>
  <reference>
    <citation>Esnault P, Cungi PJ, Romanat PE, D'Aranda E, Cotte J, Bordes J, Vichard A, Aguillon P, Sailliol A, Meaudre E. [Blood transfusion on battlefield. The Kabul hospital experience]. Ann Fr Anesth Reanim. 2013 Oct;32(10):670-5. doi: 10.1016/j.annfar.2013.06.007. Epub 2013 Aug 13. French.</citation>
    <PMID>23953835</PMID>
  </reference>
  <reference>
    <citation>Ausset S, Meaudre E, Kaiser E, Sailliol A, Hugard L, Jeandel P. [Acute traumatic haemorrhagic shock and transfusion: the French army policy]. Ann Fr Anesth Reanim. 2009 Jul-Aug;28(7-8):707-9. doi: 10.1016/j.annfar.2009.05.011. Epub 2009 Jul 3. French.</citation>
    <PMID>19577407</PMID>
  </reference>
  <reference>
    <citation>McGuigan R, Spinella PC, Beekley A, Sebesta J, Perkins J, Grathwohl K, Azarow K. Pediatric trauma: experience of a combat support hospital in Iraq. J Pediatr Surg. 2007 Jan;42(1):207-10.</citation>
    <PMID>17208567</PMID>
  </reference>
  <reference>
    <citation>Sailliol A, Clavier B, Cap A, Ausset S. [French European military haemovigilance guidelines]. Transfus Clin Biol. 2010 Dec;17(5-6):315-7. doi: 10.1016/j.tracli.2010.09.001. Epub 2010 Nov 3. French.</citation>
    <PMID>21051263</PMID>
  </reference>
  <reference>
    <citation>Nair PM, Pidcoke HF, Cap AP, Ramasubramanian AK. Effect of cold storage on shear-induced platelet aggregation and clot strength. J Trauma Acute Care Surg. 2014 Sep;77(3 Suppl 2):S88-93. doi: 10.1097/TA.0000000000000327.</citation>
    <PMID>25159368</PMID>
  </reference>
  <reference>
    <citation>Pidcoke HF, Spinella PC, Ramasubramanian AK, Strandenes G, Hervig T, Ness PM, Cap AP. Refrigerated platelets for the treatment of acute bleeding: a review of the literature and reexamination of current standards. Shock. 2014 May;41 Suppl 1:51-3. doi: 10.1097/SHK.0000000000000078. Review.</citation>
    <PMID>24662779</PMID>
  </reference>
  <reference>
    <citation>Nair PM, Pandya SG, Dallo SF, Reddoch KM, Montgomery RK, Pidcoke HF, Cap AP, Ramasubramanian AK. Platelets stored at 4°C contribute to superior clot properties compared to current standard-of-care through fibrin-crosslinking. Br J Haematol. 2017 Jul;178(1):119-129. doi: 10.1111/bjh.14751. Epub 2017 Jun 4.</citation>
    <PMID>28580719</PMID>
  </reference>
  <reference>
    <citation>Bahr MP, Yazer MH, Triulzi DJ, Collins RA. Whole blood for the acutely haemorrhaging civilian trauma patient: a novel idea or rediscovery? Transfus Med. 2016 Dec;26(6):406-414. doi: 10.1111/tme.12329. Epub 2016 Jun 29. Review.</citation>
    <PMID>27357229</PMID>
  </reference>
  <reference>
    <citation>Cotton BA, Podbielski J, Camp E, Welch T, del Junco D, Bai Y, Hobbs R, Scroggins J, Hartwell B, Kozar RA, Wade CE, Holcomb JB; Early Whole Blood Investigators. A randomized controlled pilot trial of modified whole blood versus component therapy in severely injured patients requiring large volume transfusions. Ann Surg. 2013 Oct;258(4):527-32; discussion 532-3. doi: 10.1097/SLA.0b013e3182a4ffa0. Erratum in: Ann Surg. 2014 Jul;260(1):178.</citation>
    <PMID>23979267</PMID>
  </reference>
  <reference>
    <citation>Jenkins D, Stubbs J, Williams S, Berns K, Zielinski M, Strandenes G, Zietlow S. Implementation and execution of civilian remote damage control resuscitation programs. Shock. 2014 May;41 Suppl 1:84-9. doi: 10.1097/SHK.0000000000000133.</citation>
    <PMID>24662783</PMID>
  </reference>
  <reference>
    <citation>Stubbs JR, Zielinski MD, Jenkins D. The state of the science of whole blood: lessons learned at Mayo Clinic. Transfusion. 2016 Apr;56 Suppl 2:S173-81. doi: 10.1111/trf.13501.</citation>
    <PMID>27100754</PMID>
  </reference>
  <reference>
    <citation>Yazer MH, Jackson B, Sperry JL, Alarcon L, Triulzi DJ, Murdock AD. Initial safety and feasibility of cold-stored uncrossmatched whole blood transfusion in civilian trauma patients. J Trauma Acute Care Surg. 2016 Jul;81(1):21-6. doi: 10.1097/TA.0000000000001100.</citation>
    <PMID>27120323</PMID>
  </reference>
  <reference>
    <citation>Seheult JN, Triulzi DJ, Alarcon LH, Sperry JL, Murdock A, Yazer MH. Measurement of haemolysis markers following transfusion of uncrossmatched, low-titre, group O+ whole blood in civilian trauma patients: initial experience at a level 1 trauma centre. Transfus Med. 2017 Feb;27(1):30-35. doi: 10.1111/tme.12372. Epub 2016 Oct 12.</citation>
    <PMID>27730689</PMID>
  </reference>
  <reference>
    <citation>Savage SA, Zarzaur BL, Pohlman TH, Brewer BL, Magnotti LJ, Croce MA, Lim GH, Martin AC. Clot dynamics and mortality: The MA-R ratio. J Trauma Acute Care Surg. 2017 Oct;83(4):628-634. doi: 10.1097/TA.0000000000001637.</citation>
    <PMID>28930957</PMID>
  </reference>
  <reference>
    <citation>Einersen PM, Moore EE, Chapman MP, Moore HB, Gonzalez E, Silliman CC, Banerjee A, Sauaia A. Rapid thrombelastography thresholds for goal-directed resuscitation of patients at risk for massive transfusion. J Trauma Acute Care Surg. 2017 Jan;82(1):114-119. doi: 10.1097/TA.0000000000001270.</citation>
    <PMID>27805995</PMID>
  </reference>
  <reference>
    <citation>Gonzalez E, Moore EE, Moore HB, Chapman MP, Chin TL, Ghasabyan A, Wohlauer MV, Barnett CC, Bensard DD, Biffl WL, Burlew CC, Johnson JL, Pieracci FM, Jurkovich GJ, Banerjee A, Silliman CC, Sauaia A. Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy: A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays. Ann Surg. 2016 Jun;263(6):1051-9. doi: 10.1097/SLA.0000000000001608.</citation>
    <PMID>26720428</PMID>
  </reference>
  <reference>
    <citation>Ince C, Boerma EC, Cecconi M, De Backer D, Shapiro NI, Duranteau J, Pinsky MR, Artigas A, Teboul JL, Reiss IKM, Aldecoa C, Hutchings SD, Donati A, Maggiorini M, Taccone FS, Hernandez G, Payen D, Tibboel D, Martin DS, Zarbock A, Monnet X, Dubin A, Bakker J, Vincent JL, Scheeren TWL; Cardiovascular Dynamics Section of the ESICM. Second consensus on the assessment of sublingual microcirculation in critically ill patients: results from a task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2018 Mar;44(3):281-299. doi: 10.1007/s00134-018-5070-7. Epub 2018 Feb 6.</citation>
    <PMID>29411044</PMID>
  </reference>
  <reference>
    <citation>Tachon G, Harrois A, Tanaka S, Kato H, Huet O, Pottecher J, Vicaut E, Duranteau J. Microcirculatory alterations in traumatic hemorrhagic shock. Crit Care Med. 2014 Jun;42(6):1433-41. doi: 10.1097/CCM.0000000000000223.</citation>
    <PMID>24561562</PMID>
  </reference>
  <reference>
    <citation>Tanaka S, Escudier E, Hamada S, Harrois A, Leblanc PE, Vicaut E, Duranteau J. Effect of RBC Transfusion on Sublingual Microcirculation in Hemorrhagic Shock Patients: A Pilot Study. Crit Care Med. 2017 Feb;45(2):e154-e160. doi: 10.1097/CCM.0000000000002064.</citation>
    <PMID>27635767</PMID>
  </reference>
  <reference>
    <citation>Tanaka S, Harrois A, Nicolaï C, Flores M, Hamada S, Vicaut E, Duranteau J. Qualitative real-time analysis by nurses of sublingual microcirculation in intensive care unit: the MICRONURSE study. Crit Care. 2015 Nov 6;19:388. doi: 10.1186/s13054-015-1106-3.</citation>
    <PMID>26542952</PMID>
  </reference>
  <reference>
    <citation>Zatta AJ, McQuilten ZK, Mitra B, Roxby DJ, Sinha R, Whitehead S, Dunkley S, Kelleher S, Hurn C, Cameron PA, Isbister JP, Wood EM, Phillips LE; Massive Transfusion Registry Steering Committee. Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion. Vox Sang. 2014 Jul;107(1):60-70. doi: 10.1111/vox.12121. Epub 2014 Apr 2.</citation>
    <PMID>24697251</PMID>
  </reference>
  <reference>
    <citation>Godier A, Samama CM, Susen S. [Management of massive bleeding in 2013: seven questions and answers]. Transfus Clin Biol. 2013 May;20(2):55-8. doi: 10.1016/j.tracli.2013.02.015. Epub 2013 Apr 12. French.</citation>
    <PMID>23587620</PMID>
  </reference>
  <reference>
    <citation>Hamada SR, Rosa A, Gauss T, Desclefs JP, Raux M, Harrois A, Follin A, Cook F, Boutonnet M; Traumabase® Group, Attias A, Ausset S, Boutonnet M, Dhonneur G, Duranteau J, Langeron O, Paugam-Burtz C, Pirracchio R, de St Maurice G, Vigué B, Rouquette A, Duranteau J. Development and validation of a pre-hospital &quot;Red Flag&quot; alert for activation of intra-hospital haemorrhage control response in blunt trauma. Crit Care. 2018 May 5;22(1):113. doi: 10.1186/s13054-018-2026-9.</citation>
    <PMID>29728151</PMID>
  </reference>
  <reference>
    <citation>Nunez TC, Voskresensky IV, Dossett LA, Shinall R, Dutton WD, Cotton BA. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma. 2009 Feb;66(2):346-52. doi: 10.1097/TA.0b013e3181961c35.</citation>
    <PMID>19204506</PMID>
  </reference>
  <reference>
    <citation>Pommerening MJ, Goodman MD, Holcomb JB, Wade CE, Fox EE, Del Junco DJ, Brasel KJ, Bulger EM, Cohen MJ, Alarcon LH, Schreiber MA, Myers JG, Phelan HA, Muskat P, Rahbar M, Cotton BA; MPH on behalf of the PROMMTT Study Group. Clinical gestalt and the prediction of massive transfusion after trauma. Injury. 2015 May;46(5):807-13. doi: 10.1016/j.injury.2014.12.026. Epub 2015 Feb 4.</citation>
    <PMID>25682314</PMID>
  </reference>
  <reference>
    <citation>Yazer MH, Delaney M, Doughty H, Dunbar NM, Al-Riyami AZ, Triulzi DJ, Watchko JF, Wood EM, Yahalom V, Emery SP. It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies. Transfusion. 2019 Dec;59(12):3794-3799. doi: 10.1111/trf.15569. Epub 2019 Oct 18.</citation>
    <PMID>31625172</PMID>
  </reference>
  <reference>
    <citation>Martinaud C, Civadier C, Ausset S, Verret C, Deshayes AV, Sailliol A. In vitro hemostatic properties of French lyophilized plasma. Anesthesiology. 2012 Aug;117(2):339-46. doi: 10.1097/ALN.0b013e3182608cdd.</citation>
    <PMID>22739764</PMID>
  </reference>
  <reference>
    <citation>Raux M, Le Manach Y, Gauss T, Baumgarten R, Hamada S, Harrois A, Riou B, Duranteau J, Langeron O, Mantz J, Paugam-Burtz C, Vigue B; TRAUMABASE Group. Comparison of the Prognostic Significance of Initial Blood Lactate and Base Deficit in Trauma Patients. Anesthesiology. 2017 Mar;126(3):522-533. doi: 10.1097/ALN.0000000000001490.</citation>
    <PMID>28059838</PMID>
  </reference>
  <reference>
    <citation>Régnier MA, Raux M, Le Manach Y, Asencio Y, Gaillard J, Devilliers C, Langeron O, Riou B. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology. 2012 Dec;117(6):1276-88. doi: 10.1097/ALN.0b013e318273349d.</citation>
    <PMID>23168430</PMID>
  </reference>
  <reference>
    <citation>Manikis P, Jankowski S, Zhang H, Kahn RJ, Vincent JL. Correlation of serial blood lactate levels to organ failure and mortality after trauma. Am J Emerg Med. 1995 Nov;13(6):619-22.</citation>
    <PMID>7575797</PMID>
  </reference>
  <reference>
    <citation>Abramson D, Scalea TM, Hitchcock R, Trooskin SZ, Henry SM, Greenspan J. Lactate clearance and survival following injury. J Trauma. 1993 Oct;35(4):584-8; discussion 588-9.</citation>
    <PMID>8411283</PMID>
  </reference>
  <reference>
    <citation>Smith IM, Crombie N, Bishop JR, McLaughlin A, Naumann DN, Herbert M, Hancox JM, Slinn G, Ives N, Grant M, Perkins GD, Doughty H, Midwinter MJ; RePHILL Trial Collaborators. RePHILL: protocol for a randomised controlled trial of pre-hospital blood product resuscitation for trauma. Transfus Med. 2018 Oct;28(5):346-356. doi: 10.1111/tme.12486. Epub 2017 Nov 28.</citation>
    <PMID>29193548</PMID>
  </reference>
  <reference>
    <citation>Boutonnet M, Abback P, Le Saché F, Harrois A, Follin A, Imbert N, Cap AP, Trichereau J, Ausset S; Traumabase Group. Tranexamic acid in severe trauma patients managed in a mature trauma care system. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S54-S62. doi: 10.1097/TA.0000000000001880.</citation>
    <PMID>29538226</PMID>
  </reference>
  <reference>
    <citation>Riou B, Thicoïpe M, Atain-Kouadio P, Carli P. Comment evaluer la gravité? In: France S de, editor. Actualités en réanimation préhospitalière, Paris: Société française d'éditions médicales; 2002.</citation>
  </reference>
  <reference>
    <citation>Duranteau J, Asehnoune K, Pierre S, Ozier Y, Leone M, Lefrant J-Y. Recommandations sur la réanimation du choc hémorragique. Anesthésie &amp; Réanimation 2015;1:62-74. https://doi.org/10.1016/j.anrea.2014.12.007.</citation>
  </reference>
  <reference>
    <citation>Massive transfusion in trauma guidelines. American College of Surgeons. Quality improvement project: trauma resuscitation best practice guidelines. Chicago (IL): American College of Surgeons 2013.</citation>
  </reference>
  <reference>
    <citation>Miller RD. Massive blood transfusions: the impact of Vietnam military data on modern civilian transfusion medicine. Anesthesiology. 2009 Jun;110(6):1412-6. doi: 10.1097/ALN.0b013e3181a1fd54. Review.</citation>
    <PMID>19417598</PMID>
  </reference>
  <reference>
    <citation>Brohi K, Levy H, Boffard K, Riou B, Kiepert P, Zielske D. Normalization of lactate within 8 hours or ≥20% clearance in initial 2 hours correlates with outcomes from traumatic hemorrhagic shock. Critical Care Medicine 2011;39:177.</citation>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Whole Blood</keyword>
  <keyword>Acute traumatic coagulopathy</keyword>
  <keyword>Transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

